Wireless Eye Implant restores Reading Vision to Patients with Macular Degeneration
Table of Contents
A groundbreaking new device combining a tiny wireless chip implanted in the eye with advanced smart glasses has partially restored vision to individuals suffering from advanced age-related macular degeneration,offering a beacon of hope for millions facing irreversible blindness. Published on October 20 in the New England Journal of Medicine, the clinical trial demonstrated that 27 of 32 participants regained the ability to read within one year of receiving the implant.
A Milestone in Restoring Functional Vision
The implant, dubbed PRIMA and developed at Stanford Medicine, represents the frist prosthetic eye device capable of restoring usable vision to those with otherwise untreatable vision loss. Unlike previous attempts that only achieved light sensitivity, PRIMA enables patients to recognize shapes and patterns – a level of vision known as form vision. “All previous attempts to provide vision with prosthetic devices resulted in basically light sensitivity, not really form vision,” explained a senior researcher involved in the study. “We are the first to provide form vision.”
The research was a collaborative effort,co-led by experts at Stanford Medicine,the University of pittsburgh School of Medicine,and the University of Bonn in Germany.
How the PRIMA System Works
The PRIMA system operates through a two-part process. A small camera, integrated into a pair of glasses, captures visual data and projects it as infrared light onto the implanted chip. This chip, measuring just 2 by 2 millimeters, than converts the light into electrical signals that bypass the damaged photoreceptors and directly stimulate the remaining retinal neurons.
This innovative approach capitalizes on the fact that, even in cases of advanced macular degeneration, many of the neurons responsible for processing visual information remain intact. The project is the culmination of decades of scientific effort, involving extensive prototyping, animal testing, and initial human trials. The concept originated two decades ago, when one of the
“It may take several months of training to reach top performance – which is similar to what cochlear implants require to master prosthetic hearing,” one of the study’s authors explained. Of the 32 patients who completed the one-year trial, 27 were able to read, and 26 exhibited clinically meaningful improvements in visual acuity, defined as reading at least two additional lines on a standard eye chart. Participants experienced an average enhancement of five lines, with one individual achieving a remarkable improvement of 12 lines.
Patients were able to utilize the prosthesis in everyday activities,such as reading books,food labels,and public transportation signage. The glasses’ adjustable contrast, brightness, and magnification capabilities (up to 12x) further enhanced usability. Two-thirds of participants reported medium to high satisfaction with the device.
Side Effects and Future Progress
Nineteen participants experienced some side effects, including ocular hypertension, tears in the peripheral retina, and subretinal hemorrhage.Though, none of these were life-threatening, and the majority resolved within two months.
currently, the PRIMA device provides black-and-white vision. Researchers are actively developing software to enable grayscale vision, a crucial step towards improving face recognition – a top priority for patients. Furthermore, engineers are working on chips with higher resolution, aiming to reduce pixel size from the current 100 microns to as small as 20 microns, perhaps increasing pixel count from 378 to 10,000 per chip. A chip with 20-micron pixels could potentially deliver 20/80 vision, with electronic zoom capable of approaching 20/20.
Researchers also plan to investigate the device’s potential for treating other forms of blindness caused by photoreceptor loss.”This is the first version of the chip, and resolution is relatively low,” a lead researcher stated. “The next generation of the chip, with smaller pixels, will have better resolution and be paired with sleeker-looking glasses.”
The study involved contributions from researchers across numerous institutions in Germany, France, the United Kingdom, Italy, Luxembourg, Belgium, and the United States, highlighting the global collaborative effort driving this groundbreaking innovation. Funding for the study was provided by Science Corp., the National Institute for Health and Care Research, Moorfields Eye hospital National Health Service Foundation Trust, and University college London Institute of Ophthalmology.